Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
EARLY_PHASE1
50 participants
INTERVENTIONAL
2025-06-11
2025-12-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Treatments on Pain and Quality of Life in Individual With Burning Mouth Syndrome
NCT06040190
Neurogenic Mechanisms in Burning Mouth Syndrome
NCT00875537
Efficacy of Melatonin in Burning Mouth Syndrome (BMS)
NCT02580734
Study Evaluating the Laser Diode Effect Burning Mouth Syndrome
NCT02757612
Identification of Pathophysiological Pathways and Therapeutic Targets in Primary Stomatodynia by Salivary Metabolomics
NCT04704128
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This research study aims to evaluate how an oral cooling spray, currently a commercial dietary supplement, impacts symptoms associated with burning mouth syndrome (BMS). This study will examine symptoms, frequency, and severity, along with other related side effects of BMS on food intake, enjoyment, and quality of life.
What are some of the important aspects of this research study that I should be aware of?
Timeframe: 2 weeks intervention
Use the oral cooling spray; "Dr.B's Elixir" as directed
Participants will report symptoms and other related impacts of BMS on a weekly online survey
Optional: complete a phone interview at the end of the 2-weeks intervention period (\~30-60 minutes)
Optional: provide saliva samples (2 collections)
Compensation: No monetary compensation is provided
Direct benefit to research participants: Participants may experience changes in symptoms commonly experienced by BMS, but this is not guaranteed.
Who can participate in this research study?
We expect to enroll 30-50 individuals.
The eligibility criteria are:
At least 18 years old
Having been diagnosed with burning mouth syndrome or suffer from chronic oral burn without any identifiable causative lesion
No tongue or cheek piercings
No history of cancer
No recent or scheduled dental treatment
No history of gum disease
No aversions to mint or hop extracts
The exclusion criteria are:
Have recently undergone dental treatment in the last 3 months or have plans to undergo dental treatment (e.g., fillings, crowns, root canals, extractions, or other dental procedures) in the coming month.
Have started any new treatments for BMS in the last 3 months or have plans to start new treatments in the coming month.
What will I be asked to do, and how much time will it take?
The study will take place remotely in the comfort of your own home or residence. The study takes place over two weeks. Over the two weeks, you will use the oral spray 3 times per day with 5 sprays directly into your mouth on a single application and you can use up to 5 additional sprays as needed during each application. You will be completing an online questionnaire each week about symptoms related to BMS. This questionnaire is anticipated to take 5-10 minutes to complete. At the end of the 2nd week, participants have the option of participating in a phone interview which is anticipated to take approximately 30-60 minutes.
In total this is roughly an hour and a half if you participate in the entire study including the optional phone interview.
Optional: Phone interview
Participants have the option of participating in a phone interview - approximately 30-60 minutes at the end of the 2-weeks intervention period.
Optional: Salivary samples
Participants have the option to provide two salivary samples. The purpose of collecting saliva samples is to determine if the oral spray impacts the saliva composition compared to before its use. One sample will be collected before the oral cooling spray and one at the end of the two weeks. Then we will be doing shotgun metagenomics to analyze the total DNA content of the microbial community in the saliva samples. With this information, we can explore the oral microbiome which may be related to symptoms, taste, and flavor systems. For example, BMS has been associated with prevalent levels of "streptococcus", and it is expected that this oral spray may impact the levels of oral streptococcus.
Participants indicating consent to provide saliva samples will have saliva kits mailed along with the oral spray. After the end of the study, participants will drop the package in the mail. Return packaging and postage will be included. Participants will mail back the saliva kits with the pre-paid postage.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Oral spray
Oral spray
Oral cooling spray
Use oral spray 3 times per day for 2 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oral cooling spray
Use oral spray 3 times per day for 2 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Live in the United States
* At least 18 years old
* Having been diagnosed or suspected diagnosis of burning mouth syndrome or suffer from chronic oral burn without any identifiable causative lesion
* No tongue or cheek piercings
* No history of cancer
* No recent or scheduled dental treatment
* No history of gum disease
* No aversions to mint or hop extracts
Exclusion Criteria
* Have started any new treatments for BMS in the last 3 months or have plans to start new treatments in the coming month.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Massachusetts, Amherst
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Alissa Nolden
Assistant Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UMass Amherst
Amherst, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
6052
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.